EUCTR2008-000783-16-FR进行中（未招募）不适用
Multicenter, phase II trial assessing the efficacy and safety of bevacizumab (Avastin®) combined to trastuzumab (Herceptin®) based chemotherapy in patients with primary inflammatory HER2+ breast cancer - BEVERLY 2
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- ROCHE SAS
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •Patients must have signed a written informed consent form prior to any study specific screening procedures,
- •18 years or older,
- •Performance status 0 to 2,
- •Life expectancy = 3 months,
- •Able to comply with the protocol,
- •Patient affiliated to the national Social Security” regimen or beneficiary of this regimen.
- •Histologically confirmed breast cancer and confirmed inflammatory breast cancer defined as follows:
- •-T4d any N
- •-or PeV II IGR
- •-or PeV III IGR
- •-or skin biopsy with tumor emboles in the lymph vessels of the superficial derma.
- •HER2 positive tumors by immunohistochemistry (IHC +++) or fluorescent/chromogenic in situ hybridization (FISH+ or CISH+)
- •Hormone receptors status known.
- •No metastases.
- •Adequate hematologic function:
- •- Absolute neutrophil count = 1.2 x 10exp9/L AND
- •- platelets = 100 x 10exp9/L AND
- •- Hb = 9 g/dL
- •Adequate liver function:
- •- Total bilirubin = 1.5 ULN unless elevation is due to Gilbert’s disease or similar syndrome involving slow conjugation of bilirubin AND
- •- ASAT < 2.5 ULN AND
- •- ALAT < 2.5 ULN
- •Adequate kidney function:
- •-Serum creatinine = 1.25 ULN or Creatinine clearance = 50 mL/min according to the Cockroft and Gault formula AND
- •-Urine dipstick for proteinuria < 2+. Patients discovered to have = 2+ proteinuria on dipstick urinalysis at baseline should undergo a 24 hour urine collection and must demonstrate = 1 g of protein in 24 hours
- •Adequate coagulation function
- •-International normalized ratio (INR) = 1.5 (except for patients with prophylactic use of anticoagulant) and
- •- TCA = 1.5 x ULN within 7 days prior to enrolment.
- •Adequate cardiac function
- •-Left ventricular ejection fraction (LVEF) = 55% (isotopic or ultrasound methods)
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Incapacitated adults not able to give informed legal consent.
- •Pregnant or breast feeding women.
- •Women with an intact uterus (unless amenorrhoeic for the last 24 months) not using effective means of contraception
- •Patient considered socially or psychologically unable to comply with the treatment and the required medical follow-up.
- •Non inflammatory breast cancer with lymphatic skin permeation.
- •Metastases.
- •Previous Cancer History
- •Previous history of cancer (other than curatively treated basal and squamous cell carcinoma of the skin and/or in-situ carcinoma of the cervix) relapsing within the 5 years before study entry or in situ contralateral breast carcinoma.
- •Patient previously treated with chemotherapy, radiation therapy or hormone therapy for a breast tumor.
- •History or evidence of inherited bleeding diathesis or coagulopathy.
- •Uncontrolled hypertension (systolic >150 mmHg and/or diastolic >100 mmHg), with or without anti-hypertensive medication. Patients with high initial blood pressure are eligible if entry criteria are met after initiation or adjustment of antihypertensive medication.
- •Clinically significant (i.e. active) cardiovascular disease, i.e. myocardial infarction within the last 6 months before inclusion, unstable angina, congestive heart failure NYHA Class = II, serious cardiac arrhythmia requiring medication during the study which might interfere with regularity of the study treatment or not controlled by medication.
- •History of thrombotic disorders within the last 6 months prior to enrolment (i.e. cerebrovascular accident, transient ischaemic attacks).
- •Severe resting dyspnea due to complications or oxygen dependency.
- •Diabetic patient treated with oral antidiabetics or insulin with an underlying cardiopathy at ultrasound.
- •Evidence of ongoing or active infection (requiring IV antibiotics), any other disease, neurological or metabolic dysfunction, physical examination finding or laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or increases the patient’s risk of treatment-related complications.
- •Major surgery (including open biopsy), significant traumatic injury within 28 days prior to study treatment start or anticipation of the need for major surgery during study treatment.
- •Minor surgery, including insertion of an indwelling catheter, within 24 hours prior to the first bevacizumab infusion.
- •Non-healing wound, active peptic ulcer or bone fracture
- •History of abdominal fistula, diagnosed with a tracheo-oesophageal fistula or any grade 4 non-gastrointestinal fistula, gastrointestinal perforation or intra-abdominal abscess within 6 months of enrolment.
- •Current Medication
- •Current or recent use of any non-steroidal anti inflammatory agent (aspirin > 325 mg/day), or anti aggregation agents (dypiridamole, ticlopidine, clopidogrel > 75 mg/day), within 10 days before the first administration of bevacizumab.
- •Current or recent (within 10 days of first dose of bevacizumab) use of full dose oral or parenteral anticoagulants or thrombolytic agent for therapeutic purposes. Prophylactic use of anticoagulants is allowed.
- •Patient with known contra-indication to radiotherapy.
- •Treatment with any other investigational agent, or participation in another clinical trial within 28 days prior to enrolment.
- •Vaccination by modified live vaccines, vaccination against yellow fever during study treatment period.
研究者
相似试验
招募中
不适用
A Multi-center Phase II Study evaluating efficacy and safety of Dasatinib in Patients with newly diagnosed Philadelphia(Ph) chromosome positive Chronic Myeloid Leukemia in chronic phase.Chronic Myeloid LeukemiaJPRN-UMIN000005843Epidemiological and Clinical Research Information Network (ECRIN)30
进行中（未招募）
1 期
Study assessing if a chemotherapy drug called Cabazitaxel is effective in Patients with certain type of breast cancer (HER2 negative) that has spread to brain that is un treatable.Her-2 negative breast cancer with brain metastasesMedDRA version: 14.1Level: LLTClassification code 10027475Term: Metastatic breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1Level: PTClassification code 10055113Term: Breast cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2012-000542-35-GBThe Clatterbridge Cancer Centre NHS Foundation Trust19
已完成
2 期
Efficacy of cabazitaxel in patients with HER2-negative metastatic breast cancerPatients with HER2-negative metastatic breast cancer and having unresectable brain metastases.Malignant neoplasm of breastCancerISRCTN79877830The Clatterbridge Cancer Centre NHS Foundation Trust (UK)19
招募中
1 期
Multicenter Phase 2 study to evaluate the efficacy and safety of Cetuximab in combination with Encorafenib plus Binimetinib as induction treatment in BRAF (V600E) mutated MSS, initially resectable or potentially resectable advanced colorectal cancer: CEBBRA study.BRAF V600E mutated and microsatellite stable (MSS) advanced colorectal cancer (aCRC) initially resectable or potentially resectableMedDRA version: 21.0Level: PTClassification code: 10052360Term: Colorectal adenocarcinoma Class: 100000004864CTIS2022-502413-29-00Asociacion Grupo Tratamiento De Tumores Digestivos70
已完成
2 期
Multicenter phase II trial to assess clinical benefit of zoledronic acid with neo adjuvant endocrine treatment and the relationship between zoledronic acid use and gammadelta T cells for postmenopausal breast cancer.Postmenopausal ER positive and HER2 negative primary breast cancerJPRN-UMIN000008701Breast Surgery, Graduate School of Medicine, Kyoto University75